PROM1 and malignant colon neoplasm: Certain oncogenic factors that drive tumor growth have been suggested to stimulate CD133 transcription, and the ability of celecoxib to downregulate colon cancer CD133 might occur by inhibiting such oncogenic signaling molecules [40].